Methods: We examined 820 lung adenocarcinoma (LUAD) samples that had matched PD-L1 staining and received genomic profiling to measure tumor mutational burden (TMB) and genomic alterations in 315 genes (FM cohort). We also examined progression free survival (PFS) of 1310 CI treated patients in a HIPAA compliant, real world clinicogenomic database (CGDB). These patients received the FoundationOne assay as part of routine care and had electronic health record data available in the Flatiron Health Database (Singal, ASCO 2017). Results: In the CGDB, we observed known associations between likelihood of PFS and TMB, loss of STK11. TMB correlated with median PFS in months (mPFS): TMB > 20 mutations per MB (N ¼ 164) -6 mo vs TMB < ¼20 (N ¼ 1146) -2.8 mo, P ¼ 1e-07). Patients with STK11 loss had reduced mPFS (wt 3.1 mo vs mut 2.5 mo, P ¼ 0.01). We analyzed PDL1 staining for driver alterations in LUADs in the FM cohort. EGFR mutant samples were enriched for PDL1 negative staining (FM cohort: P ¼ 6.3e-5) and the EGFR cohort had reduced mPFS (CGDB: wt 3 mo vs mut 2.4 mo, P ¼ 0.003). Samples with MET exon 14 skipping mutations were enriched for PDL1 high positive staining (FM: P ¼ 2.3e-5), but the MET cohort had similar mPFS (CGDB: wt 3 mo vs mut 2.7 mo, P ¼ 0.8). Samples with BRAF alterations trended towards both PDL1 high positive staining (FM: P ¼ 0.06) and increased mPFS (CGDB: wt 2.9 mo vs mut 4.6 mo, P ¼ 0.2). Conclusions: We examined PFS of NSCLC patients on CI therapies in a clinicogenomic database and observed known associations with TMB, STK11 and EGFR alterations. We found that, at a population level, MET altered patients did not have enhanced mPFS despite increased PDL1 HP staining, suggesting dual or targeted therapies. Realworld datasets such as the CGDB hold promise in prioritizing therapies and identifying biomarkers of response and resistance. Legal entity responsible for the study: Foundation Medicine Inc., Cambridge, Massachusetts, United States of America. Background: PD-1/PDL-1-blockade by nivolumab is a promising and efficacious treatment for mNSCLC patients. It acts by rescuing PD-1-inactivated tumor-infiltratinglymphocytes, an event indispensable for a short-term antitumor response. Nevertheless, continuous immune-priming is needed to avoid clonal-T-cell exhaustion and to prolong patient survival. We have investigated, whether class-I/II HLA homo/ heterozygosis, antigen cascade and cross-priming measured as auto-antibody (AAbs) rise may predict patient outcomes with nivolumab treatment. Methods: This is a retrospective study including ninety-eight mNSCLC patients who received nivolumab (3mg/kg every 15 days) between September 2015 and March 2018 as a second line of treatment. Log-rank test and Mantel-Cox analysis were carried out to correlate PFS and OS with homo/heterozygosis HLA status, respectively, for locus A, B, C and DrB1 and baseline and post-treatment levels of AAbs [anti-nuclear antibodies (ANA), extractable nuclear antigen (ENA), anti-smooth cell antigen (ASMA), antineutrophil cytoplasmic antigens (ANCA)]. Results: A PFS and OS of ) months, were, respectively, recorded. They were not correlated with histology, sex or previous radiotherapy. HLA-DrB1 heterozygosis showed a significant advantage in OS (HR ¼ 0.18, 95%CI:0.036-0.902; p ¼ 0.037). A prolonged survival was also found in patients who showed early rise (within thirty days) of one (score 1, HR ¼ 0.235, 95% CI: 0.084-0.654. P ¼ 0.018) or more AAbs (score 2, HR ¼ 0.22, 95% CI: 0.081-0.624, P ¼ 0.001). Finally, Cox analysis revealed a predictive role for treatment-related early increase in eosinophil cell counts (OS, HR: 0.68, 95% CI: 0.57-0.81, P ¼ 0.031). Conclusions: Heterozygosis in the HLA-DrB1 locus and early rise in ANA, ENA and/or ASMA is predictive of longer OS in nivolumab-treated mNSCLC patients. These data support the hypothesis that continuous and efficient tumor antigen-release and crosspriming during PD1/PDL-1 blockade is critical for long-term patient survival. These results offer a strong rationale to design future immunotherapy trials in NSCLC patients. Legal entity responsible for the study: Grande Ospedale Metropolitano "BianchiMelacrino-Morelli", Reggio Calabria, Italy. Funding: Has not received any funding. Disclosure: All authors have declared no conflicts of interest.
Background: PD-1/PDL-1-blockade by nivolumab is a promising and efficacious treatment for mNSCLC patients. It acts by rescuing PD-1-inactivated tumor-infiltratinglymphocytes, an event indispensable for a short-term antitumor response. Nevertheless, continuous immune-priming is needed to avoid clonal-T-cell exhaustion and to prolong patient survival. We have investigated, whether class-I/II HLA homo/ heterozygosis, antigen cascade and cross-priming measured as auto-antibody (AAbs) rise may predict patient outcomes with nivolumab treatment. Methods: This is a retrospective study including ninety-eight mNSCLC patients who received nivolumab (3mg/kg every 15 days) between September 2015 and March 2018 as a second line of treatment. Log-rank test and Mantel-Cox analysis were carried out to correlate PFS and OS with homo/heterozygosis HLA status, respectively, for locus A, B, C and DrB1 and baseline and post-treatment levels of AAbs [anti-nuclear antibodies (ANA), extractable nuclear antigen (ENA), anti-smooth cell antigen (ASMA), antineutrophil cytoplasmic antigens (ANCA)]. Results: A PFS and OS of 13.68 (95%CI:10.85 -16.5) and 16.41 (95%CI:13.48-19.34) months, were, respectively, recorded. They were not correlated with histology, sex or previous radiotherapy. HLA-DrB1 heterozygosis showed a significant advantage in OS (HR ¼ 0.18, 95%CI:0.036-0.902; p ¼ 0.037). A prolonged survival was also found in patients who showed early rise (within thirty days) of one (score 1, HR ¼ 0.235, 95% CI: 0.084-0.654. P ¼ 0.018) or more AAbs (score 2, HR ¼ 0.22, 95% CI: 0.081-0.624, P ¼ 0.001). Finally, Cox analysis revealed a predictive role for treatment-related early increase in eosinophil cell counts (OS, HR: 0.68, 95% CI: 0.57-0.81, P ¼ 0.031). Conclusions: Heterozygosis in the HLA-DrB1 locus and early rise in ANA, ENA and/or ASMA is predictive of longer OS in nivolumab-treated mNSCLC patients. These data support the hypothesis that continuous and efficient tumor antigen-release and crosspriming during PD1/PDL-1 blockade is critical for long-term patient survival. These results offer a strong rationale to design future immunotherapy trials in NSCLC patients. Legal entity responsible for the study: Grande Ospedale Metropolitano "BianchiMelacrino-Morelli", Reggio Calabria, Italy. 
